ACADIA Pharmaceuticals Inc. (ACAD) P/E Ratio History
Historical price-to-earnings valuation from 2010 to 2025
Loading P/E history...
ACAD Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a price-to-earnings ratio of 9.4x, with a stock price of $21.48 and trailing twelve-month earnings per share of $2.28.
The current P/E is 50% below its 5-year average of 18.9x. Over the past five years, ACAD's P/E has ranged from a low of 4.4x to a high of 90.3x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ACAD trades at a 58% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, ACAD trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ACAD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ACAD P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66 | +817%Best | |
| $3B | 18.7 | 0.15Best | +176% | |
| $6B | 8.6 | - | +264% | |
| $28B | 21.6 | - | -21% | |
| $6B | 24.7 | - | -34% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ACAD Historical P/E Data (2010–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $21.34 | $1.55 | 13.8x | -27% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $21.57 | $1.33 | 16.2x | -14% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $16.61 | $1.37 | 12.1x | -36% |
| FY2024 Q4 | $18.35 | $1.36 | 13.5x | -29% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $15.38 | $0.78 | 19.7x | +4% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $16.25 | $0.18 | 90.3x | +377% |
| FY2011 Q3 | Fri Sep 30 2011 00:00:00 GM | $1.08 | $0.24 | 4.4x | -77% |
| FY2011 Q2 | $1.63 | $0.23 | 7.1x | -63% | |
| FY2011 Q1 | $1.62 | $0.24 | 6.8x | -64% | |
| FY2010 Q4 | Fri Dec 31 2010 00:00:00 GM | $1.20 | $0.22 | 5.5x | -71% |
Average P/E for displayed period: 18.9x
See ACAD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACAD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACAD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
Is ACAD stock overvalued or undervalued?
ACAD trades at 9.4x P/E, below its 5-year average of 18.9x. At the 40th percentile of historical range, the stock is priced at a discount to its own history.
How does ACAD's valuation compare to peers?
ACADIA Pharmaceuticals Inc. P/E of 9.4x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is ACAD's PEG ratio?
ACAD PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2010-2025.